0000000000805680

AUTHOR

Michaela Rehrl

showing 1 related works from this author

Clinical Impact of GATA2 Mutations in Acute Myeloid Leukemia Patients Harboring CEBPA Mutations: A Study of the AML Study Group (AMLSG)

2013

Abstract Background Based on their association with certain biological and clinical features as well as their prognostic significance, mutations in the CCAAT/enhancer-binding protein-alpha (CEBPA) gene have been included as a provisional entity into the 2008 World Health Organization (WHO) classification of myeloid neoplasms. CEBPA mutations (CEBPAmut) are mainly found in acute myeloid leukemia (AML) with normal cytogenetics, and approximately 60% of the mutated patients (pts) carry biallelic mutations. Several studies showed that in particular pts with double mutant CEBPA (CEBPAdm) have a favorable outcome compared to all others. Recently, mutations in the transcription factor GATA2 were i…

OncologyNPM1medicine.medical_specialtyMyeloidbusiness.industryImmunologyMyeloid leukemiaContext (language use)Cell BiologyHematologyBiochemistryFrameshift mutationmedicine.anatomical_structureInternal medicineCEBPAGenotypemedicineMissense mutationbusinessBlood
researchProduct